Treatment complexity in cystic fibrosis: Trends over time and associations with site-specific outcomes

Journal of Cystic Fibrosis

Volumn 12, Issue 5, 2013, Pages 461-467

  Sawicki, Gregory S ^a   Ren, Clement L ^b   Konstan, Michael W ^c   Millar, Stefanie J ^d   Pasta, David J ^d   Quittner, Alexandra L ^e  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ICON Late Phase and Outcomes Research   (United States)

^e UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CHILD; CYSTIC FIBROSIS; CYSTIC FIBROSIS QUESTIONNAIRE REVISED; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LONGITUDINAL STUDY; LUNG CLEARANCE; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEBULIZATION; NUTRITIONAL STATUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POSITIVE END EXPIRATORY PRESSURE; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT COMPLEXITY SCORE;

ADOLESCENT; CHILD; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84882899722     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2012.12.009     Document Type: Article

References (17)

1. Foundation C.F. Cystic Fibrosis Foundation Patient Registry Annual Data Report 2010, Cystic Fibrosis Foundation, Bethesda, Maryland, [2011].
2. Flume P.A., O'Sullivan B.P., Robinson K.A., Goss C.H., Mogayzel P.J., Willey-Courand D.B., et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007, 176(10):957-969.
3. Flume P.A., Robinson K.A., O'Sullivan B.P., Finder J.D., Vender R.L., Willey-Courand D.B., et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care 2009, 54(4):522-537.
4. Sawicki G.S., Sellers D.E., Robinson W.M. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros 2009, 8(2):91-96.
5. Briesacher B.A., Quittner A.L., Saiman L., Sacco P., Fouayzi H., Quittell L.M. Adherence with tobramycin inhaled solution and health care utilization. BMC Pulm Med 2011, 11:5.
6. Eakin M.N., Bilderback A., Boyle M.P., Mogayzel P.J., Riekert K.A. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros 2011, 10(4):258-264.
7. Modi A.C., Lim C.S., Yu N., Geller D., Wagner M.H., Quittner A.L. A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros 2006, 5(3):177-185.
8. Sawicki G.S., Rasouliyan L., McMullen A.H., Wagener J.S., McColley S.A., Pasta D.J., et al. Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis. Pediatr Pulmonol 2011, 46(1):36-44.
9. Johnson C., Butler S.M., Konstan M.W., Morgan W., Wohl M.E. Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest 2003, 123(1):20-27.
10. Morgan W.J., Butler S.M., Johnson C.A., Colin A.A., FitzSimmons S.C., Geller D.E., et al. Epidemiologic Study of Cystic Fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol 1999, 28(4):231-241.
11. Hankinson J.L., Odencrantz J.R., Fedan K.B. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999, 159(1):179-187.
12. Wang X., Dockery D.W., Wypij D., Fay M.E., Ferris B.G. Pulmonary function between 6 and 18years of age. Pediatr Pulmonol 1993, 15(2):75-88.
13. Quittner A.L., Buu A., Messer M.A., Modi A.C., Watrous M. Development and validation of the Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 2005, 128(4):2347-2354.
14. Quittner A.L., Sawicki G.S., McMullen A., Rasouliyan L., Pasta D.J., Yegin A., et al. Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample. Qual Life Res 2012 Sep, 21(7):1279-1290.
15. Konstan M.W., Ratjen F. Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis. J Cyst Fibros 2012, 11(2):78-83.
16. Sawicki G.S., Tiddens H. Managing treatment complexity in cystic fibrosis: challenges and opportunities. Pediatr Pulmonol 2012, 47(6):523-533.
17. Quittner A.L., Schechter M.S., Rasouliyan L., Haselkorn T., Pasta D.J., Wagener J.S. Impact of socioeconomic status, race, and ethnicity on quality of life in patients with cystic fibrosis in the United States. Chest 2010, 137(3):642-650.